<DOC>
	<DOCNO>NCT00840203</DOCNO>
	<brief_summary>The objective study evaluate relative bioavailability test formulation mesalamine suspension rectal enema already market reference formulation RowasaÂ® healthy , adult subject .</brief_summary>
	<brief_title>Mesalamine 4 gm/60 mL Rectal Enema</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Males female , 18 year old , body mass index ( BMI ) 30 less . Good health determine lack clinically significant abnormality health assessment perform screen . Signed informed consent form , meet criteria current FDA regulation . If female child bear potential prepared abstain sexual intercourse use reliable method contraception study ( e.g . condom , IUD , hormonal contraceptive ) . If female pregnant , lactating , likely become pregnant study . History allergy sensitivity mesalamine salicylic drug ( e.g . aspirin , sulfasalazine ) history drug hypersensitivity intolerance , opinion Investigator , would compromise safety subject study . Colitis , hemorrhoid , anal fissure , disease anus , rectum colon . Significant history current evidence chronic infection disease , system disorder organ disorder . History psychiatric disorder occur within last two year require hospitalization medication . Presence medical condition require regular treatment prescription drug ( contraceptive ) . Use pharmacologic agent know significantly induce inhibit drugmetabolizing enzyme within 30 day prior dose . Receipt drug part research study within 30 day prior dose . Drug alcohol addiction require treatment past 12 month . Donation significant loss whole blood ( 480 mL ) within 30 day plasma within 14 day prior dose . Positive test HIV , Hepatitis B surface antigen , Hepatitis C antibody . Positive test result drug abuse screen . Positive serum pregnancy test screening . Unable unwilling tolerate multiple venipuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>